Fig. 3From: Recent advances in pre-conditioned mesenchymal stem/stromal cell (MSCs) therapy in organ failure; a comprehensive review of preclinical studiesThe application of genetically modified mesenchymal stem/stromal cells (MSCs) in organ failure. Adrenomedullin (ADM), Heme oxygenase-1 (HO-1), Vascular endothelial growth factor 165 (VEGF165), Hypoxia-inducible factor 1α (HIF-1α), MicroRNA133 (miR-133), Interleukin-35 (IL-35)Back to article page